Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
Adult
Aged
Antibodies, Viral
/ analysis
Antigens, CD20
/ immunology
COVID-19
/ complications
Female
Humans
Immunity, Cellular
Immunity, Humoral
Immunoglobulin G
/ analysis
Interferon-gamma
/ biosynthesis
Male
Middle Aged
Multiple Sclerosis
/ complications
Nucleocapsid
/ chemistry
Retrospective Studies
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
20
08
2021
accepted:
21
12
2021
entrez:
2
2
2022
pubmed:
3
2
2022
medline:
11
2
2022
Statut:
epublish
Résumé
Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS. This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2. A total of 121 (83.45%) of 145 PwMS were seropositive, and 25/42 (59.5%) presented a cellular response up to 13.1 months after COVID-19. Anti-CD20-treated patients had lower antibody titers than those under other DMTs ( Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti-CD20-treated patients, even in the absence of antibodies.
Sections du résumé
BACKGROUND AND OBJECTIVES
Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS.
METHODS
This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2.
RESULTS
A total of 121 (83.45%) of 145 PwMS were seropositive, and 25/42 (59.5%) presented a cellular response up to 13.1 months after COVID-19. Anti-CD20-treated patients had lower antibody titers than those under other DMTs (
DISCUSSION
Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti-CD20-treated patients, even in the absence of antibodies.
Identifiants
pubmed: 35105687
pii: 9/2/e1143
doi: 10.1212/NXI.0000000000001143
pmc: PMC8808353
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, CD20
0
Immunoglobulin G
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Mult Scler Relat Disord. 2021 Oct;55:103157
pubmed: 34418737
J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):24-31
pubmed: 34341142
Clin Exp Immunol. 2020 Nov;202(2):149-161
pubmed: 32671831
Eur J Neurol. 2021 Oct;28(10):3384-3395
pubmed: 33340215
Nature. 2021 Jul;595(7867):359-360
pubmed: 34127832
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
JAMA Neurol. 2021 Jul 1;78(7):880-882
pubmed: 33929488
Neurology. 2021 Nov 9;97(19):e1870-e1885
pubmed: 34610987
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738
Nature. 2021 Jul;595(7867):421-425
pubmed: 34030176
Sci Rep. 2020 Sep 14;10(1):14991
pubmed: 32929138
Clin Infect Dis. 2021 Nov 2;73(9):e3130-e3132
pubmed: 33035306
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 28;8(5):
pubmed: 34321333
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Ther Adv Neurol Disord. 2021 Apr 22;14:17562864211012835
pubmed: 34035836
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
EBioMedicine. 2021 Oct;72:103581
pubmed: 34563483
Clin Infect Dis. 2021 Oct 05;:
pubmed: 34609506
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
J Infect Chemother. 2021 Jun;27(6):808-813
pubmed: 33531292
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Mult Scler. 2021 Jul 30;:13524585211035318
pubmed: 34328824
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
J Infect Dis. 2021 Aug 16;224(4):586-594
pubmed: 33978754
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
Ann Neurol. 2021 Apr;89(4):780-789
pubmed: 33480077
Autoimmun Rev. 2021 Sep;20(9):102893
pubmed: 34237417
Mult Scler. 2017 Oct;23(11):1506-1516
pubmed: 28273769